IHC immunohistochemistry assay regulatory update

The U.K.'s NICE now recommends the use of Oncotype DX from Genomic Health after the company said it would provide the breast cancer diagnostic at an undisclosed discount under a patient access scheme. In draft guidance released earlier this month, NICE said it recommends use of Oncotype DX to guide decisions about chemotherapy use in women with estrogen receptor-positive, lymph node-negative, HER2-negative early breast cancer who are at intermediate risk of distant recurrence. ...